GlassScriptPhysician profile
Michele J Moraes
NPI 1023029477
$5,109.88
in general payments reported to CMS, 2019-2025
38 companies · $507 in 2025
The $507 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $934 · 2020: $328 · 2021: $770 · 2022: $1,174 · 2023: $792 · 2024: $605 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,903.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $675.54 | 2021-2024 | Opzelura |
| Abbvie INC. | $626.04 | 2019-2025 | |
| Amgen INC. | $584.76 | 2020-2025 | Otezla |
| Almirall LLC | $523.65 | 2019-2025 | Seysara, Klisyri |
| Novo Nordisk INC | $469.80 | 2019-2022 | |
| Pfizer INC. | $401.39 | 2021-2023 | |
| Genzyme Corporation | $218.65 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $163.99 | 2019-2022 | |
| Esperion Therapeutics, INC. | $138.63 | 2021 | |
| Janssen Scientific Affairs, LLC | $119.81 | 2022 | |
| Celgene Corporation | $116.27 | 2019 | |
| Lilly USA, LLC | $105.35 | 2019-2023 | Taltz |
| Janssen Biotech, INC. | $91.86 | 2022-2023 | Remicade, Simponi Aria, Simponi |
| Amarin Pharma, INC. | $82.51 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $80.54 | 2024-2025 | Dupixent, Libtayo |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Moraes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.